BACKGROUND Despite the availability of different therapeutic modalities, treatment of recalcitrant common warts is still challenging. Cervarix (GlaxoSmithKline, Brentford, UK), a recombinant bivalent human papillomavirus (HPV) vaccine, has shown promising efficacy in the treatment of warts. OBJECTIVES To evaluate the beneficial effects and tolerability of intramuscular versus intralesional bivalent HPV vaccine in the treatment of recalcitrant common warts. METHODS The study included 44 adult patients with multiple recalcitrant common warts; 22 patients received intramuscular injection of bivalent HPV vaccine at 0, 1, and 6 months or until complete clearance of warts, and the other 22 patients received intralesional injection of 0.1 to 0.3 mL of bivalent HPV vaccine into the largest wart at 2-week intervals until complete clearance or for a maximum of 6 sessions. RESULTS Complete clearance of warts was observed in 18 patients (81.8%) of the intralesional group and 14 patients (63.3%) of the intramuscular group; however, the difference was not statistically significant. Adverse effects were transient and insignificant, and no recurrence was reported in either group. LIMITATIONS Small study sample and different dosing schedules. CONCLUSIONS Bivalent HPV vaccine, particularly by intralesional injection, seems to be a potential therapeutic option for the treatment of multiple recalcitrant common warts.

中文翻译：

---

病灶内与肌肉内二价人乳头瘤病毒疫苗治疗顽固性寻常疣。

背景尽管有不同的治疗方式，顽固性寻常疣的治疗仍然具有挑战性。Cervarix（葛兰素史克公司，布伦特福德，英国）是一种重组二价人乳头瘤病毒 (HPV) 疫苗，在治疗疣方面显示出良好的疗效。目的 评估肌肉注射和病灶内注射二价 HPV 疫苗治疗顽固性寻常疣的有益效果和耐受性。方法 该研究包括 44 名患有多发顽固性寻常疣的成年患者；22 例患者在 0、1 和 6 个月或直至完全清除疣时接受二价 HPV 疫苗肌内注射，另外 22 例患者接受 0.1 至 0 的病灶内注射。每隔 2 周将 3 毫升二价 HPV 疫苗注射到最大的疣体中，直至完全清除或最多注射 6 次。结果 病灶内注射组 18 例 (81.8%) 和肌肉注射组 14 例 (63.3%) 观察到疣完全清除；然而，差异在统计学上并不显着。不良反应是短暂且微不足道的，两组均未报告复发。局限性 小研究样本和不同的给药方案。结论 二价 HPV 疫苗，特别是通过病灶内注射，似乎是治疗多发性顽固性寻常疣的潜在治疗选择。差异无统计学意义。不良反应是短暂且微不足道的，两组均未报告复发。局限性 小研究样本和不同的给药方案。结论 二价 HPV 疫苗，特别是通过病灶内注射，似乎是治疗多发性顽固性寻常疣的潜在治疗选择。差异无统计学意义。不良反应是短暂且微不足道的，两组均未报告复发。局限性 小研究样本和不同的给药方案。结论 二价 HPV 疫苗，特别是通过病灶内注射，似乎是治疗多发性顽固性寻常疣的潜在治疗选择。